Allos Therapeutics Inc

Allos Therapeutics — Merger or Acquisition (July 2011)

15 slides from Allos Therapeutics's merger presentation, Jul 20, 2011

  1. Slide 1: AMAG Pharmaceuticals and Allos Therapeutics to Merge

    I N V E S T O R P R E S E N T A T I O N AMAG Pharmaceuticals and Allos Therapeutics to Merge p g July 20, 2011 Creates Company With Strengthened Commercial Portfolio 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This communication contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “esti

  3. Slide 3: Important Merger Information and Where to Find It

    Important Merger Information and Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. The proposed merger between AMAG and Allos will be submitted to the re

  4. Slide 4: Merger Highlights

    Merger Highlights 4 Terms • Stock for stock transaction • 0 1282 AMAG shares for each Allos Allos stockholders will receive 0.1282 share held; total equity value of approximately $686 million Ownership at Closing • AMAG 61% / Allos 39% Cash Position • 30 373 7M; June 30, 2011 combined cash and inves

  5. Slide 5: Financial and Strategic Benefits of Merger

    Financial and Strategic Benefits of Merger . Combined company will have a diversified portfolio of commercial products 5 focused on high-potential markets with overlapping customer segments . FERAHEME® (ferumoxytol injection) – for the treatment of iron deficiency anemia (IDA) in adult patients with

  6. Slide 6: Two Commercial Products with Compelling Value

    Two Commercial Products with Compelling Value FERAHEME FOLOTYN Description . Therapeutic iron formulation delivered via intravenous (IV) injection . U S l J . Folate analogue metabolic inhibitor delivered via intravenous (IV) injection . U S l S t b Propositions 6 U.S. approval June 2009 U.S. approv

  7. Slide 7: FERAHEME and FOLOTYN Have Attractive Opportunities for Continued Growth

    FERAHEME and FOLOTYN Have Attractive Opportunities for Continued Growth and Value Creation, Sharing Many Common Call Points Market detail Non-dialysis CKD Incidence 7 . The overall U.S. non-dialysis IV iron market is estimated to be $400 million . 1.6 million Americans are estimated to have non-dial

  8. Slide 8: Strengthened Commercial Company Expected to Leverage Customer Relationships

    Strengthened Commercial Company Expected to Leverage Customer Relationships for Brands . Products: FERAHEME and FOLOTYN 8 . Address attractive markets with targeted sales force . Improved share of voice . Target call points include hematology / oncology infusion centers, g p gy/ gy , community clini

  9. Slide 9: Global Development Programs Expected to Drive Expanded Market Opportunities

    Global Development Programs Expected to Drive Expanded Market Opportunities . Strategic collaborations outside the U.S. with industry leaders — with T k d i l U S i d 3Sbi i Chi f FERAHEME d 9 Takeda in several ex-U.S. regions and 3Sbio in China for FERAHEME, and Mundipharma for FOLOTYN ex-U.S. and

  10. Slide 10: Multiple Milestones Provide Future Growth Opportunities

    Multiple Milestones Provide Future Growth Opportunities 2H 2011 Mil t 2012 Mil t 10 . CHMP recommendation expected for EU MAA for IDA in CKD D i i t d di C di . sNDA submission to FDA and EMA for broad IDA indication Milestones Milestones EME ME . Decision expected regarding Canadian regulatory appl

  11. Slide 11: Potential for Significant Milestone Payments and Royalties from Established Collaborations

    Potential for Significant Milestone Payments and Royalties from Established Collaborations FERAHEME FOLOTYN 11 . Takeda: Strategic alliance for developments and commercialization of FERAHEME . $60 million upfront payment received in 2010 . Up to $220 million in potential development and milestones $

  12. Slide 12: Combined Company Expected to Realize Annual Synergies of $55 to $60 Million

    Combined Company Expected to Realize Annual Synergies of $55 to $60 Million Expected Annual Primary Driver 12 Synergies Selling, General and Administrative $38 mm - $41 mm .Rationalization of redundant public company expenses (includes facilities rationalization) . Rationalization of redundant perso

  13. Slide 13: 2010 Net Product Revenues

    2010 Net Product Revenues 2010 Net Product Revenue ($MM) 2010 Net Product Revenue Contribution % 13 FOLOTYN 90 100 60 70 80 30 40 50 FERAHEME 0 10 20 FERAHEME FOLOTYN Combined

  14. Slide 14: Financial and Strategic Benefits of Merger

    Financial and Strategic Benefits of Merger . Combined company will have a diversified portfolio of commercial d f d hi h i l k i h l i 14 products focused on high-potential markets with overlapping customer segments . FERAHEME® (ferumoxytol injection) – for the treatment of iron deficiency anemia (I

  15. Slide 15: AMAG Pharmaceuticals and Allos Therapeutics to Merge

    I N V E S T O R P R E S E N T A T I O N AMAG Pharmaceuticals and Allos Therapeutics to Merge p g July 20, 2011 Creates Company With Strengthened Commercial Portfolio

Allos Therapeutics — Merger or Acquisition (July 2011) on 6ix